The case of a 35-year-old 
Background

Patients taking psychiatric therapy are prone to gain weight often accompanied by an increase in appetite or food hunger. It is hard to foresee its occurrence and timing, and thus this side effect frequently results in obesity and
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to research the efficiency of nutritional support in curing potential physical, hormonal and metabolic disorders. (6) (7) (8) .
Method
Weight gain caused by a psychotropic drug often precedes a sudden increase in appetite and the preference for sweet and greasy food (9) . This condition was established by Paykel who first made use of the term "carbohydrate craving" (10) . If a person is suffering from excessive food craving, the associated increase in food consumption is a potential reason for weight gain. Many authors reported that gaining weight is correlated with the enhancement of clinical symptoms (11, 12) . In a study conducted by Czobor et al (13) , the positive relation which was found between weight gain and the antipsychotic effect of clozapine and olanzap-ine could not be associated with the risperidone and haloperidol therapy.
It was suggested that psychotropic drugs which cause weight gain, activate the TNF-α system (14) and thus the TNF-α system is an early and sensitive indicator of weight gain (15 (17) . (20) (19, (23) (24) (25) (26) .
It is also suggested that weight gain caused by psychotropic drug therapy could be associated with an increase in the leptin levels. During acute treatment of schizophrenia with clozapine, the serum leptin increased by two fold two weeks after the start of therapy and remained at a high level during the first 10 weeks. Meanwhile, body weight was increased by an average of 4.2 kg (18). In patients treated with clozapine or olanzapine for 4 weeks, weight gain of 2.3 and 3.9 kg, respectively, was observed and in conformity with increased leptin secretion. It was also detected that patients treated with haloperidol or not using psychotropic drugs did not gain weight and had constant leptin levels (19). Among second generation antipsychotic drugs, clozapine and olanzapine are considered to have a high risk for impaired glucose metabolism. This condition was first recognized with the reporting of many cases in which diabetic ketoacidosis developed as a result of clozapine therapy, was cured with the discontinuation of clozapine therapy and then relapsed with the recommencement of therapy. In a study
Potentials for an increase in weight for any drugs would be initially recommended to increase the patient's adaptation to the psychotropic drug and to reduce the metabolic risks of weight gain. Diet, exercise and changes in lifestyle are considered to be the gold standards of the obesity therapy (27, 28 
